Spiramycin (Rovamycin) 是由链霉菌 (Streptomyces ambofaciens) 产生的大环内酯抗生素,具有抗细菌和抗弓形虫的作用,并具有抗寄生虫作用。Spiramycin (Rovamycin) 由 16 个内酯环组成,其上附着三种糖 (mycaminose,forosamine 和 mycarose)。
生物活性 | Spiramycin (Rovamycin) is a macrolideantibioticproduced byStreptomyces ambofacienswith againstbacteriaandToxoplasmagondiiactivities, and also has antiparasitic effect. Spiramycin is composed of a 16-member lactone ring, on which three sugars (mycaminose, forosamine, and mycarose) are attached[1][2]. |
IC50& Target | |
体外研究 (In Vitro) | Spiramycin (24 hours; 1-1000 μM;T. gondiiinfected HeLa cells and HeLa cells) treatment reduces the cytotoxicity, and shows anti-Toxoplasma gondiiactivity, withIC50values of 189 μM for HeLa cells; and 262 μM forT. gondii-infected HeLa cells[3].
Cell Cytotoxicity Assay[3] Cell Line: | T. gondiiinfected HeLa cells and HeLa cells | Concentration: | 1-1000 μM | Incubation Time: | 24 hours | Result: | Reduced the cytotoxicity. |
|
体内研究 (In Vivo) | Spiramycin (100 mg/kg; intraperitoneal injection; every day; for 4 days; female KM mice) treatment reduces the number of tachyzoites, and reduces hepatotoxicity and significantly enhances antioxidative effects. Spiramycin treatment also decreases in the degree of granulomatous inflammation in the liver[3].
Animal Model: | 36 female KM mice withT.gondii[3] | Dosage: | 100 mg/kg | Administration: | Intraperitoneal injection; every day; for 4 days | Result: | The number of tachyzoites was significantly reduced. Reduced hepatotoxicity and significantly enhanced antioxidative effects. Granuloma and cyst formation were inhibitied. |
|
Clinical Trial | |
分子量 | |
性状 | |
Formula | |
CAS 号 | |
中文名称 | |
结构分类 | - Antibiotics
- Macrolide Antibiotics
|
来源 | |
运输条件 | Room temperature in continental US; may vary elsewhere. |
储存方式 | Powder | -20°C | 3 years | | 4°C | 2 years | In solvent | -80°C | 6 months | | -20°C | 1 month |
|
溶解性数据 | In Vitro: DMSO : ≥ 100 mg/mL(118.62 mM) *"≥" means soluble, but saturation unknown. 配制储备液 1 mM | 1.1862 mL | 5.9308 mL | 11.8617 mL | 5 mM | 0.2372 mL | 1.1862 mL | 2.3723 mL | 10 mM | 0.1186 mL | 0.5931 mL | 1.1862 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80℃, 6 months; -20℃, 1 month。-80℃ 储存时,请在 6 个月内使用,-20℃ 储存时,请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议您现用现配,当天使用;
以下溶剂前显示的百 分比是指该溶剂在您配制终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂: 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.5 mg/mL (2.97 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (2.97 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中,混合均匀;向上述体系中加入50 μL Tween-80,混合均匀;然后继续加入 450 μL生理盐水定容至 1 mL。 2. 请依序添加每种溶剂: 10% DMSO 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.5 mg/mL (2.97 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (2.97 mM,饱和度未知) 的澄清溶液。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL20% 的 SBE-β-CD 生理盐水水溶液中,混合均匀。 3. 请依序添加每种溶剂: 10% DMSO 90%corn oil Solubility: ≥ 2.5 mg/mL (2.97 mM); Clear solution
此方案可获得 ≥ 2.5 mg/mL (2.97 mM,饱和度未知) 的澄清溶液,此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例,取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中,混合均匀。 *以上所有助溶剂都可在本网站选购。
|